Validation and Clinical Application of a Liquid Chromatography–Ultraviolet Detection Method to Quantify Dolutegravir in Dried Blood Spots
| Autor: | Abdulafeez Akinloye, Oluwasegun I. Eniayewu, Adeniyi Olagunju, Oluseye O. Bolaji, Babatunde Ayodeji Adeagbo |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Pharmacology
Chromatography Spots Pyridones Chemistry Cmax Reproducibility of Results Piperazines chemistry.chemical_compound Pharmacokinetics Potassium phosphate Oxazines Dolutegravir Humans Pharmacology (medical) Dried Blood Spot Testing Dried blood Heterocyclic Compounds 3-Ring Chromatography High Pressure Liquid Finger prick Chromatography Liquid Whole blood |
| Zdroj: | THERAPEUTIC DRUG MONITORING |
| ISSN: | 0163-4356 |
| DOI: | 10.1097/ftd.0000000000000929 |
| Popis: | BACKGROUND Dolutegravir is currently the preferred component of first-line antiretroviral therapy. To facilitate clinical pharmacology studies in key populations, quantitative analytical methods compatible with microsampling and adaptable to resource-limited settings are desirable. The authors developed and validated a liquid chromatography-ultraviolet detection method to quantify dolutegravir in dried blood spots (DBS). METHODS Calibration standards and quality control samples were prepared by spotting 50 μL of dolutegravir-spiked whole blood on each circle of DBS cards. Three spots (two 6-mm punches/spot) were extracted with methanol. Chromatographic separation was achieved with gradient elution of acetonitrile/potassium phosphate monobasic buffer (pH 5) on a reverse-phase C18 column (flow rate, 1 mL/min) using pioglitazone as the internal standard. UV detection was performed at 260 nm. In the clinical pharmacokinetic study, DBS from finger prick was collected from participants (n = 10) at 8 time points over 12 h post-dosing, with paired plasma at 1 and 12 h. The method was used to quantify dolutegravir, estimating pharmacokinetic parameters. Agreement between DBS and plasma concentrations was evaluated using linearity and Bland-Altman plots. RESULTS The method was validated over the concentration range of 0.4-10 µg/mL, accuracy was 102.4-114.8%, and precision was 3.4-14.7%. The mean recovery was 42.3% (%CV: 8.3). The mean (±standard deviation) dolutegravir concentration in DBS was 37.5% (±3.8%) lower than that in the plasma. DBS-derived and measured plasma concentrations showed strong correlation with linearity (R2 = 0.9804) and Bland-Altman plots. Means (%CV) of AUC, Cmax, and C24 from the DBS-derived plasma concentration were 37.8 (23.2) μg.h/mL, 2.7 (24.7) μg/mL and 1.34 (31.6) μg/mL, respectively. CONCLUSIONS The application of this simple, accurate, and precise method will expand opportunities for clinical assessment of dolutegravir in resource-limited settings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|